Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 120.3%.

  • BridgeBio Pharma's EBITDA Margin rose 68983700.0% to 120.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 172.39%, marking a year-over-year increase of 775900.0%. This contributed to the annual value of 267.22% for FY2024, which is 62615300.0% up from last year.
  • Per BridgeBio Pharma's latest filing, its EBITDA Margin stood at 120.3% for Q3 2025, which was up 68983700.0% from 121.45% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's EBITDA Margin peaked at 19953.49% during Q4 2021, and registered a low of 38200.0% during Q3 2022.
  • Its 5-year average for EBITDA Margin is 6756.95%, with a median of 6377.94% in 2021.
  • Examining YoY changes over the last 5 years, BridgeBio Pharma's EBITDA Margin showed a top increase of 1244526700bps in 2021 and a maximum decrease of -388120600bps in 2021.
  • BridgeBio Pharma's EBITDA Margin (Quarter) stood at 19953.49% in 2021, then tumbled by -135bps to 6910.8% in 2022, then tumbled by -47bps to 10167.11% in 2023, then skyrocketed by 62bps to 3842.69% in 2024, then skyrocketed by 97bps to 120.3% in 2025.
  • Its EBITDA Margin was 120.3% in Q3 2025, compared to 121.45% in Q2 2025 and 89.49% in Q1 2025.